TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HBM Holdings Ltd. ( (HK:2142) ) just unveiled an update.
HBM Holdings Ltd. has announced a non-exclusive license agreement with Pfizer, allowing Pfizer global access to Nona Biosciences’ HCAb platform for preclinical antibody discovery. This collaboration aims to accelerate the development of fully human heavy chain-only antibodies for various disease indications, potentially enhancing HBM’s industry positioning and offering milestone payments that could benefit stakeholders.
The most recent analyst rating on (HK:2142) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.
More about HBM Holdings Ltd.
HBM Holdings Ltd. is a company incorporated in the Cayman Islands, focusing on the biotechnology industry. It operates through its subsidiary, Nona Biosciences, which specializes in antibody discovery and development using its proprietary HCAb platform.
Average Trading Volume: 8,231,219
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.21B
For a thorough assessment of 2142 stock, go to TipRanks’ Stock Analysis page.